Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Hexarelin vs Somapacitan (Sogroya)
An educational, source-based comparison of Hexarelin and Somapacitan (Sogroya) — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic hexapeptide and potent GHS-R agonist. Stimulates GH release more strongly than GHRP-6 and shows cardioprotective signaling in preclinical ischemia-reperfusion models, partly independent of GH.
- GH release
- Cardiac ischemia-reperfusion (preclinical)
- Left ventricular function in animal models
- • Not FDA-approved.
- • Tachyphylaxis with prolonged use.
- • Prohibited by WADA.
Once-weekly growth hormone analog for adults and children with GHD.
GH analog with a non-covalent albumin-binding side chain that extends half-life, enabling once-weekly subcutaneous administration with sustained IGF-1 elevation.
- Adult growth hormone deficiency
- Pediatric GH deficiency
- • FDA-approved.
- • Monitor glucose; injection-site reactions possible.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Hexarelin | Hexarelin and the cardiovascular system | Cardiovascular Research | 2006 | Reviewed direct cardioprotective effects of hexarelin in animal models. |
| Somapacitan (Sogroya) | REAL trials | JCEM | 2020 | Comparable body composition and IGF-1 response to daily somatropin. |
Side-effect & safety grid
- Not FDA-approved.
- Tachyphylaxis with prolonged use.
- Prohibited by WADA.
- FDA-approved.
- Monitor glucose; injection-site reactions possible.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Hexarelin vs Somapacitan (Sogroya) — Key differences
- Class: Hexarelin is classified as Growth Hormone Axis · Cardiac, while Somapacitan (Sogroya) is GH Analog · Endocrine.
- Primary research focus: Hexarelin — gh release; Somapacitan (Sogroya) — adult growth hormone deficiency.
- Tag: Growth hormone vs FDA-Approved · Endocrine.